Peter Attia· MD
rapamycin could reduce the morbidity of covid19 by 50 percent
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
rapamycin could reduce the morbidity of covid19 by 50 percent
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
so it's at least I think suggestive of the idea that Rapa continuous use throughout the period of infection and resolution of symptoms it may be associated with a lower likelihood of severity of outcome and lower likelihood of long covid and again I think that might make sense in the context of at least how how at a at a crude level we kind of think Co long Co in particular is working and severe covid infections which is there's this hyperinflammatory or chronic inflammatory response it kind of makes sense that rapy use may have benefits in the context of that prolonged in inflammation or hyperinflammatory response
statistically significant between people who took Romy throughout and all of the other groups where people who took Romy throughout had lower severity of infection and the numbers were really small so we I don't want to make too much of it but signif statistically significantly less likelihood of reporting symptoms associated with long Co
and again I think that might make sense in the context of at least how how at a at a crude level we kind of think long covet in particular is working in severe covet infections which is there's this hyperinflammatory or chronic inflammatory response it kind of makes sense that rapamycin use may have benefits in the context of that prolonged inflammation or hyperinflammatory response
people who took rapamycin throughout had lower severity of infection and the numbers were really small so we I don't want to make too much of it but statistically significantly less likelihood of reporting symptoms associated with long covid
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.